Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FDG · 1 trial · 1 indication
Identification of structures with increased \[18F\]FDG uptake (SUVmax) corresponding to pain.
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | \[18F\]FDG PET/MRI |
| Name | Type | Description |
|---|---|---|
| [18F]FDG | DRUG | 10 mCi of \[18F\]FDG via the antecubital vein in a bolus injection |
| PET/MRI | DEVICE | PET/MRI hybrid scanner used as diagnostic device |
Inclusion Criteria: * Age 18 years or older. * Chronic pain lasting greater than 2 months. For example: Low back pain, sciatica, complex regional pain syndrome, peripheral nerve injury, fibromyalgia, neuropathy, osteoarthritis, cancer pain, persistent post-operative pain, and migraine. * Provides i...
FDG is a small molecule being investigated for use in chronic pain. It is being studied as a diagnostic imaging agent in a clinical trial that uses PET/MR imaging to evaluate patients with chronic pain. The drug is currently in Phase 1 clinical development.
FDG is being developed by GE HealthCare Technologies Inc., a company publicly traded under the ticker symbol GEHC. The company is conducting clinical research to evaluate the use of FDG in patients with chronic pain.
FDG is currently in Phase 1 clinical development. It has completed one Phase 1 trial, which was an uncontrolled study with 88 participants. The drug is investigational and has not yet been approved for any use.
FDG has been studied in one clinical trial with the identifier NCT03195270, titled "Use of PET/MR Imaging in Chronic Pain." This Phase 1 study was completed in the United States and enrolled 88 participants aged 18 years and older.
FDG is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for chronic pain. The completed trial was an early-stage study, and the drug has not yet received regulatory approval for any indication.